According to Affimed 's latest financial reports the company's current revenue (TTM) is $8.95 M. In 2022 the company made a revenue of $43.14 M a decrease over the years 2021 revenue that were of $46.97 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $8.95 M | -79.24% |
2022 | $43.14 M | -8.16% |
2021 | $46.97 M | 40.94% |
2020 | $33.33 M | 38.9% |
2019 | $23.99 M | -11.8% |
2018 | $27.2 M | 1071.46% |
2017 | $2.32 M | -66.78% |
2016 | $6.99 M | -16.19% |
2015 | $8.34 M | 88.33% |
2014 | $4.42 M | -36.68% |
2013 | $6.99 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Repligen
RGEN | $0.63 B | 7,030.53% | ๐บ๐ธ USA |
Merrimack Pharmaceuticals MACK | N/A | N/A | ๐บ๐ธ USA |
Agenus
AGEN | $0.15 B | 1,644.92% | ๐บ๐ธ USA |
Acorda Therapeutics
ACOR | $0.11 B | 1,213.14% | ๐บ๐ธ USA |